| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Arrhythmia Agents | 55 | 2016 | 89 | 8.760 |
Why?
|
| Drug Approval | 19 | 2013 | 34 | 6.640 |
Why?
|
| United States Food and Drug Administration | 36 | 2014 | 70 | 6.520 |
Why?
|
| Drug Industry | 21 | 2013 | 28 | 5.070 |
Why?
|
| Electrocardiography | 49 | 2015 | 198 | 4.640 |
Why?
|
| Clinical Trials as Topic | 26 | 2014 | 366 | 4.540 |
Why?
|
| United States | 72 | 2014 | 1991 | 4.390 |
Why?
|
| Amiodarone | 18 | 2016 | 28 | 4.210 |
Why?
|
| Pharmaceutical Preparations | 10 | 2012 | 18 | 4.140 |
Why?
|
| Arrhythmias, Cardiac | 36 | 2010 | 128 | 4.100 |
Why?
|
| Humans | 213 | 2018 | 25732 | 3.880 |
Why?
|
| Device Approval | 8 | 2014 | 16 | 3.860 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 12 | 2018 | 32 | 3.590 |
Why?
|
| Heart Failure | 14 | 2015 | 177 | 3.130 |
Why?
|
| Drug Design | 6 | 2014 | 36 | 3.030 |
Why?
|
| Tachycardia | 33 | 2013 | 43 | 2.900 |
Why?
|
| Equipment Design | 8 | 2014 | 177 | 2.770 |
Why?
|
| Research | 12 | 2014 | 61 | 2.710 |
Why?
|
| Equipment and Supplies | 5 | 2011 | 14 | 2.630 |
Why?
|
| Diuretics | 6 | 2009 | 13 | 2.570 |
Why?
|
| Drug Prescriptions | 8 | 2008 | 23 | 2.550 |
Why?
|
| Hypertension | 8 | 2015 | 212 | 2.470 |
Why?
|
| Atrial Fibrillation | 9 | 2016 | 120 | 2.250 |
Why?
|
| Long QT Syndrome | 7 | 2011 | 13 | 2.220 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 5 | 2008 | 8 | 2.080 |
Why?
|
| Caffeine | 3 | 2015 | 61 | 2.070 |
Why?
|
| Cardiovascular Agents | 6 | 2015 | 24 | 2.060 |
Why?
|
| Sotalol | 7 | 2016 | 7 | 1.990 |
Why?
|
| Periodicals as Topic | 5 | 2015 | 35 | 1.990 |
Why?
|
| Endpoint Determination | 4 | 2014 | 28 | 1.850 |
Why?
|
| Patents as Topic | 4 | 2014 | 5 | 1.790 |
Why?
|
| Blood Pressure | 18 | 2015 | 208 | 1.750 |
Why?
|
| Cardiovascular Diseases | 7 | 2014 | 300 | 1.710 |
Why?
|
| Publishing | 4 | 2015 | 34 | 1.630 |
Why?
|
| Drug Labeling | 4 | 2010 | 6 | 1.560 |
Why?
|
| Politics | 5 | 2010 | 18 | 1.560 |
Why?
|
| Research Support as Topic | 5 | 2013 | 21 | 1.550 |
Why?
|
| Legislation, Drug | 5 | 2008 | 5 | 1.530 |
Why?
|
| Myocardial Infarction | 10 | 2009 | 167 | 1.470 |
Why?
|
| Drug Costs | 5 | 2015 | 16 | 1.450 |
Why?
|
| Biomedical Research | 4 | 2013 | 78 | 1.420 |
Why?
|
| Delivery of Health Care | 3 | 2015 | 69 | 1.400 |
Why?
|
| Advisory Committees | 3 | 2013 | 35 | 1.370 |
Why?
|
| Central Nervous System Stimulants | 2 | 2015 | 55 | 1.370 |
Why?
|
| Analgesics | 2 | 2015 | 84 | 1.330 |
Why?
|
| Chronic Pain | 2 | 2015 | 72 | 1.320 |
Why?
|
| Product Surveillance, Postmarketing | 7 | 2010 | 17 | 1.310 |
Why?
|
| Drug Therapy | 5 | 2012 | 15 | 1.260 |
Why?
|
| Piperidines | 17 | 1987 | 33 | 1.240 |
Why?
|
| Financing, Government | 4 | 2013 | 14 | 1.230 |
Why?
|
| Heart Rate | 17 | 2015 | 140 | 1.230 |
Why?
|
| Disease Outbreaks | 3 | 2014 | 88 | 1.190 |
Why?
|
| Risk Assessment | 6 | 2014 | 674 | 1.170 |
Why?
|
| Conflict of Interest | 3 | 2013 | 18 | 1.130 |
Why?
|
| Vasodilator Agents | 5 | 2009 | 28 | 1.130 |
Why?
|
| Infusions, Intravenous | 10 | 2011 | 99 | 1.090 |
Why?
|
| Female | 69 | 2015 | 15291 | 1.070 |
Why?
|
| Male | 73 | 2015 | 14935 | 1.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2002 | 28 | 1.020 |
Why?
|
| Hypotension | 4 | 2005 | 30 | 1.020 |
Why?
|
| Health Care Reform | 2 | 2011 | 17 | 0.990 |
Why?
|
| Health Policy | 3 | 2014 | 41 | 0.970 |
Why?
|
| Benzeneacetamides | 11 | 1986 | 12 | 0.960 |
Why?
|
| Quinidine | 12 | 2007 | 14 | 0.950 |
Why?
|
| Genetic Testing | 3 | 2012 | 72 | 0.950 |
Why?
|
| Evidence-Based Medicine | 4 | 2009 | 207 | 0.950 |
Why?
|
| Animals | 27 | 2009 | 4797 | 0.940 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 300 | 0.930 |
Why?
|
| Ethacrynic Acid | 2 | 2009 | 3 | 0.930 |
Why?
|
| Edema | 2 | 2009 | 35 | 0.900 |
Why?
|
| Lidocaine | 12 | 2004 | 41 | 0.900 |
Why?
|
| Oocytes | 6 | 2008 | 14 | 0.900 |
Why?
|
| Internet | 2 | 2015 | 83 | 0.870 |
Why?
|
| Electrophysiology | 18 | 2007 | 146 | 0.850 |
Why?
|
| Sex Characteristics | 3 | 2015 | 88 | 0.840 |
Why?
|
| Drug Combinations | 2 | 2015 | 85 | 0.820 |
Why?
|
| Stroke | 2 | 2011 | 306 | 0.810 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2006 | 12 | 0.800 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2010 | 509 | 0.800 |
Why?
|
| Time Factors | 19 | 2012 | 1680 | 0.800 |
Why?
|
| Procainamide | 19 | 1987 | 20 | 0.790 |
Why?
|
| Education, Medical, Continuing | 2 | 2008 | 43 | 0.780 |
Why?
|
| Drug Interactions | 6 | 2010 | 68 | 0.780 |
Why?
|
| Digoxin | 3 | 2014 | 6 | 0.770 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2010 | 58 | 0.770 |
Why?
|
| Hypoglycemic Agents | 2 | 2010 | 64 | 0.750 |
Why?
|
| Diffusion of Innovation | 2 | 2008 | 35 | 0.740 |
Why?
|
| Hemodynamics | 11 | 2004 | 100 | 0.740 |
Why?
|
| Aminobutyrates | 1 | 2015 | 1 | 0.740 |
Why?
|
| Tetrazoles | 1 | 2015 | 6 | 0.730 |
Why?
|
| Energy Drinks | 1 | 2015 | 1 | 0.730 |
Why?
|
| Syncope, Vasovagal | 2 | 2009 | 2 | 0.730 |
Why?
|
| Coffee | 1 | 2015 | 3 | 0.730 |
Why?
|
| Drug Utilization | 3 | 2006 | 22 | 0.730 |
Why?
|
| Manometry | 1 | 2015 | 27 | 0.730 |
Why?
|
| Thyroid Gland | 1 | 2016 | 55 | 0.720 |
Why?
|
| Nicotine | 1 | 2015 | 8 | 0.720 |
Why?
|
| Global Health | 2 | 2014 | 51 | 0.720 |
Why?
|
| Research Design | 3 | 2007 | 183 | 0.720 |
Why?
|
| Diabetic Neuropathies | 1 | 2015 | 14 | 0.710 |
Why?
|
| Kidney | 2 | 2015 | 179 | 0.710 |
Why?
|
| Myocardial Ischemia | 3 | 2009 | 52 | 0.710 |
Why?
|
| Flecainide | 9 | 2008 | 12 | 0.700 |
Why?
|
| Denervation | 1 | 2015 | 20 | 0.700 |
Why?
|
| Computers | 1 | 2015 | 19 | 0.700 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 70 | 0.690 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2000 | 23 | 0.690 |
Why?
|
| Middle Aged | 52 | 2010 | 9627 | 0.690 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2014 | 8 | 0.690 |
Why?
|
| Sports | 2 | 2008 | 19 | 0.680 |
Why?
|
| Biological Products | 2 | 2007 | 28 | 0.670 |
Why?
|
| Adult | 29 | 2015 | 8409 | 0.670 |
Why?
|
| Defibrillators, Implantable | 2 | 2013 | 19 | 0.670 |
Why?
|
| Public Health | 1 | 2014 | 46 | 0.670 |
Why?
|
| Medical Device Recalls | 1 | 2014 | 3 | 0.660 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 334 | 0.660 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2009 | 55 | 0.650 |
Why?
|
| Heart Valve Prosthesis | 1 | 2014 | 31 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 302 | 0.650 |
Why?
|
| Patient Care | 1 | 2014 | 30 | 0.640 |
Why?
|
| Pain Management | 1 | 2015 | 110 | 0.640 |
Why?
|
| Sulfonamides | 4 | 2016 | 56 | 0.640 |
Why?
|
| Communication | 1 | 2015 | 91 | 0.640 |
Why?
|
| Supreme Court Decisions | 1 | 2013 | 1 | 0.630 |
Why?
|
| Equipment Safety | 2 | 2010 | 13 | 0.630 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 52 | 0.630 |
Why?
|
| Federal Government | 1 | 2013 | 4 | 0.620 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 17 | 0.620 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 12 | 0.620 |
Why?
|
| Piperazines | 3 | 2009 | 83 | 0.620 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 12 | 0.620 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 73 | 0.620 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2015 | 20 | 0.610 |
Why?
|
| Torsades de Pointes | 3 | 2011 | 11 | 0.610 |
Why?
|
| Tachycardia, Ventricular | 2 | 2004 | 24 | 0.610 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 7 | 0.610 |
Why?
|
| Cardiac Pacing, Artificial | 16 | 1987 | 47 | 0.610 |
Why?
|
| Xenopus laevis | 6 | 2008 | 10 | 0.600 |
Why?
|
| Registries | 2 | 2004 | 150 | 0.600 |
Why?
|
| Action Potentials | 4 | 2006 | 112 | 0.590 |
Why?
|
| Metagenome | 1 | 2012 | 20 | 0.580 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 100 | 0.580 |
Why?
|
| Drug and Narcotic Control | 2 | 2010 | 8 | 0.580 |
Why?
|
| Bioterrorism | 2 | 2002 | 6 | 0.570 |
Why?
|
| Antithrombins | 1 | 2011 | 6 | 0.560 |
Why?
|
| Drugs, Generic | 2 | 2002 | 4 | 0.550 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 38 | 0.550 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 4 | 0.550 |
Why?
|
| Risk Factors | 9 | 2016 | 2208 | 0.540 |
Why?
|
| Cross Infection | 1 | 2014 | 262 | 0.540 |
Why?
|
| Hypotension, Orthostatic | 2 | 2010 | 16 | 0.540 |
Why?
|
| Pediatrics | 2 | 2003 | 50 | 0.540 |
Why?
|
| Anticholesteremic Agents | 2 | 2008 | 21 | 0.530 |
Why?
|
| Drug Discovery | 1 | 2011 | 26 | 0.530 |
Why?
|
| Heart Conduction System | 7 | 2002 | 26 | 0.530 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2006 | 40 | 0.520 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2010 | 1 | 0.520 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 85 | 0.520 |
Why?
|
| Sympathomimetics | 1 | 2010 | 5 | 0.520 |
Why?
|
| Midodrine | 1 | 2010 | 2 | 0.520 |
Why?
|
| Administration, Oral | 12 | 2016 | 150 | 0.520 |
Why?
|
| Adrenergic beta-Antagonists | 7 | 2016 | 39 | 0.510 |
Why?
|
| Drug Evaluation | 10 | 2002 | 57 | 0.510 |
Why?
|
| Antihypertensive Agents | 3 | 2014 | 62 | 0.510 |
Why?
|
| Angina Pectoris | 2 | 2004 | 18 | 0.510 |
Why?
|
| Aged | 39 | 2010 | 8523 | 0.510 |
Why?
|
| Potassium | 2 | 2007 | 66 | 0.510 |
Why?
|
| Hospitalization | 2 | 2014 | 262 | 0.500 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2005 | 14 | 0.500 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 10 | 0.500 |
Why?
|
| Global Warming | 1 | 2010 | 1 | 0.500 |
Why?
|
| Decision Making | 1 | 2012 | 175 | 0.490 |
Why?
|
| Anticoagulants | 1 | 2011 | 122 | 0.490 |
Why?
|
| Therapeutic Equivalency | 5 | 2016 | 8 | 0.490 |
Why?
|
| Dementia, Vascular | 1 | 2010 | 39 | 0.490 |
Why?
|
| Muscle Contraction | 2 | 2007 | 83 | 0.480 |
Why?
|
| Technetium | 1 | 2009 | 6 | 0.480 |
Why?
|
| Cost Control | 1 | 2009 | 11 | 0.480 |
Why?
|
| Thiophenes | 1 | 2009 | 14 | 0.480 |
Why?
|
| Heart Ventricles | 18 | 2008 | 188 | 0.470 |
Why?
|
| Technology, Pharmaceutical | 1 | 2009 | 2 | 0.470 |
Why?
|
| Ventricular Function | 2 | 2008 | 14 | 0.470 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 55 | 0.470 |
Why?
|
| Neurology | 1 | 2011 | 98 | 0.460 |
Why?
|
| Insulin | 1 | 2010 | 90 | 0.460 |
Why?
|
| Ascites | 1 | 2009 | 5 | 0.460 |
Why?
|
| Medication Errors | 2 | 2000 | 19 | 0.460 |
Why?
|
| Genetics | 2 | 2006 | 2 | 0.460 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2006 | 10 | 0.460 |
Why?
|
| Methadone | 1 | 2008 | 7 | 0.460 |
Why?
|
| Patient Selection | 2 | 2007 | 227 | 0.460 |
Why?
|
| Licensure, Medical | 1 | 2008 | 2 | 0.450 |
Why?
|
| Catheter Ablation | 1 | 2009 | 44 | 0.450 |
Why?
|
| Catheterization | 1 | 2009 | 61 | 0.450 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 11 | 0.450 |
Why?
|
| Acidosis | 2 | 2005 | 4 | 0.450 |
Why?
|
| Rats | 7 | 2007 | 939 | 0.440 |
Why?
|
| Authorship | 1 | 2008 | 14 | 0.440 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 9 | 0.440 |
Why?
|
| Substance Abuse Detection | 1 | 2008 | 5 | 0.440 |
Why?
|
| Street Drugs | 1 | 2008 | 9 | 0.440 |
Why?
|
| Self Disclosure | 1 | 2008 | 12 | 0.440 |
Why?
|
| Fees and Charges | 1 | 2008 | 8 | 0.430 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 151 | 0.430 |
Why?
|
| Doping in Sports | 1 | 2008 | 2 | 0.430 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2008 | 44 | 0.430 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 29 | 0.430 |
Why?
|
| Food-Drug Interactions | 1 | 2007 | 1 | 0.430 |
Why?
|
| Flavanones | 1 | 2007 | 3 | 0.430 |
Why?
|
| Hypolipidemic Agents | 2 | 2014 | 27 | 0.420 |
Why?
|
| Beverages | 1 | 2007 | 14 | 0.420 |
Why?
|
| Heart Diseases | 2 | 2008 | 88 | 0.420 |
Why?
|
| Government Regulation | 3 | 2015 | 7 | 0.420 |
Why?
|
| Ethics Consultation | 1 | 2007 | 1 | 0.410 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 114 | 0.410 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2007 | 23 | 0.410 |
Why?
|
| Metolazone | 1 | 2007 | 1 | 0.400 |
Why?
|
| Diuresis | 1 | 2007 | 2 | 0.400 |
Why?
|
| Physician's Role | 1 | 2007 | 19 | 0.400 |
Why?
|
| Furosemide | 1 | 2007 | 2 | 0.400 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2007 | 21 | 0.400 |
Why?
|
| Myocardial Contraction | 5 | 2005 | 77 | 0.400 |
Why?
|
| Databases as Topic | 1 | 2006 | 20 | 0.390 |
Why?
|
| Social Control, Formal | 3 | 2001 | 3 | 0.390 |
Why?
|
| Patch-Clamp Techniques | 4 | 2007 | 135 | 0.390 |
Why?
|
| Retrospective Studies | 6 | 2015 | 2588 | 0.390 |
Why?
|
| Pharmacology, Clinical | 2 | 2004 | 3 | 0.390 |
Why?
|
| Gastrointestinal Tract | 1 | 2007 | 52 | 0.390 |
Why?
|
| Electrodes | 1 | 2006 | 17 | 0.380 |
Why?
|
| Information Dissemination | 2 | 2004 | 19 | 0.380 |
Why?
|
| In Vitro Techniques | 4 | 2007 | 253 | 0.380 |
Why?
|
| Electric Stimulation | 12 | 2004 | 90 | 0.380 |
Why?
|
| Security Measures | 2 | 2003 | 4 | 0.380 |
Why?
|
| Erythromycin | 1 | 2006 | 16 | 0.370 |
Why?
|
| Verapamil | 7 | 2009 | 34 | 0.370 |
Why?
|
| Natriuretic Agents | 1 | 2005 | 1 | 0.370 |
Why?
|
| Hyperkalemia | 2 | 2006 | 5 | 0.370 |
Why?
|
| Hypnotics and Sedatives | 1 | 2006 | 24 | 0.370 |
Why?
|
| Pyridines | 1 | 2006 | 44 | 0.370 |
Why?
|
| Administration, Topical | 2 | 2015 | 21 | 0.360 |
Why?
|
| Water | 2 | 2003 | 36 | 0.360 |
Why?
|
| Hypokalemia | 2 | 2005 | 7 | 0.360 |
Why?
|
| Healthy Volunteers | 2 | 2015 | 36 | 0.360 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 160 | 0.360 |
Why?
|
| Magnesium Sulfate | 1 | 2005 | 9 | 0.360 |
Why?
|
| Human Experimentation | 2 | 2002 | 2 | 0.350 |
Why?
|
| Young Adult | 4 | 2015 | 1802 | 0.350 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 292 | 0.350 |
Why?
|
| Stents | 1 | 2007 | 149 | 0.350 |
Why?
|
| Coronary Disease | 4 | 1998 | 98 | 0.340 |
Why?
|
| Ethics, Medical | 2 | 2001 | 17 | 0.340 |
Why?
|
| Anti-Obesity Agents | 1 | 2004 | 6 | 0.330 |
Why?
|
| Liability, Legal | 3 | 2012 | 6 | 0.330 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2007 | 489 | 0.330 |
Why?
|
| Heart Arrest | 4 | 1997 | 44 | 0.330 |
Why?
|
| Nonprescription Drugs | 1 | 2004 | 2 | 0.330 |
Why?
|
| Prescription Fees | 1 | 2003 | 1 | 0.320 |
Why?
|
| Imidazoles | 6 | 1987 | 65 | 0.320 |
Why?
|
| Stereoisomerism | 4 | 2008 | 22 | 0.320 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 575 | 0.320 |
Why?
|
| Publication Bias | 1 | 2003 | 6 | 0.320 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2000 | 8 | 0.310 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2003 | 2 | 0.310 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 5 | 0.310 |
Why?
|
| Teaching | 1 | 2004 | 62 | 0.310 |
Why?
|
| Electric Countershock | 5 | 2013 | 20 | 0.310 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 250 | 0.310 |
Why?
|
| Clinical Protocols | 2 | 2003 | 58 | 0.310 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2003 | 4 | 0.310 |
Why?
|
| Glyburide | 1 | 2002 | 1 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 61 | 0.300 |
Why?
|
| Metformin | 1 | 2002 | 10 | 0.300 |
Why?
|
| Clinical Competence | 1 | 2005 | 237 | 0.300 |
Why?
|
| Drug Therapy, Combination | 4 | 2009 | 250 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 2 | 2006 | 371 | 0.290 |
Why?
|
| Polymorphism, Genetic | 2 | 2002 | 90 | 0.290 |
Why?
|
| Facility Regulation and Control | 1 | 2002 | 2 | 0.290 |
Why?
|
| 1-Octanol | 1 | 2002 | 1 | 0.290 |
Why?
|
| Solvents | 1 | 2002 | 5 | 0.290 |
Why?
|
| Heart Valve Diseases | 1 | 2002 | 15 | 0.280 |
Why?
|
| Public Health Administration | 1 | 2001 | 9 | 0.280 |
Why?
|
| Disaster Planning | 1 | 2001 | 8 | 0.280 |
Why?
|
| Magnesium Compounds | 1 | 2001 | 2 | 0.280 |
Why?
|
| Emergency Medical Services | 1 | 2001 | 35 | 0.270 |
Why?
|
| Accreditation | 1 | 2001 | 13 | 0.270 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2001 | 1 | 0.270 |
Why?
|
| Orphan Drug Production | 1 | 2001 | 3 | 0.270 |
Why?
|
| Ventricular Dysfunction | 1 | 2001 | 3 | 0.270 |
Why?
|
| Stem Cells | 1 | 2001 | 48 | 0.270 |
Why?
|
| Addison Disease | 1 | 2000 | 1 | 0.260 |
Why?
|
| Government Programs | 1 | 2000 | 2 | 0.260 |
Why?
|
| Obesity | 1 | 2004 | 275 | 0.260 |
Why?
|
| Cross-Over Studies | 2 | 2010 | 68 | 0.250 |
Why?
|
| Genetic Markers | 3 | 2012 | 49 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 181 | 0.240 |
Why?
|
| Information Services | 1 | 1999 | 5 | 0.240 |
Why?
|
| Science | 1 | 1999 | 5 | 0.240 |
Why?
|
| Half-Life | 4 | 2009 | 16 | 0.240 |
Why?
|
| Potassium Channels | 3 | 2006 | 42 | 0.240 |
Why?
|
| Pharmacokinetics | 2 | 2002 | 6 | 0.230 |
Why?
|
| Circadian Rhythm | 2 | 2006 | 262 | 0.230 |
Why?
|
| Drug Hypersensitivity | 1 | 1998 | 15 | 0.220 |
Why?
|
| Biological Availability | 3 | 2009 | 24 | 0.220 |
Why?
|
| Dogs | 5 | 2004 | 273 | 0.220 |
Why?
|
| Delayed Rectifier Potassium Channels | 2 | 2007 | 5 | 0.220 |
Why?
|
| Area Under Curve | 2 | 2010 | 70 | 0.220 |
Why?
|
| Alprostadil | 1 | 1997 | 11 | 0.210 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1997 | 11 | 0.210 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1997 | 17 | 0.210 |
Why?
|
| Aged, 80 and over | 6 | 2004 | 4342 | 0.210 |
Why?
|
| Death, Sudden | 4 | 2004 | 15 | 0.210 |
Why?
|
| Heart | 5 | 1992 | 97 | 0.200 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1997 | 28 | 0.200 |
Why?
|
| Nitroglycerin | 2 | 1995 | 4 | 0.200 |
Why?
|
| Universities | 2 | 2010 | 20 | 0.190 |
Why?
|
| Risk | 4 | 2011 | 205 | 0.190 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2007 | 182 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2008 | 6 | 0.190 |
Why?
|
| Hydantoins | 2 | 2006 | 2 | 0.190 |
Why?
|
| Imidazolidines | 2 | 2006 | 2 | 0.190 |
Why?
|
| Phenethylamines | 2 | 2006 | 5 | 0.190 |
Why?
|
| Biotechnology | 1 | 2015 | 3 | 0.190 |
Why?
|
| Hypercalcemia | 3 | 2001 | 8 | 0.190 |
Why?
|
| Adolescent | 2 | 2015 | 2305 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2008 | 3215 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2006 | 751 | 0.180 |
Why?
|
| Injections, Intravenous | 7 | 2016 | 60 | 0.180 |
Why?
|
| Diclofenac | 1 | 2015 | 4 | 0.180 |
Why?
|
| Membrane Potentials | 2 | 2007 | 216 | 0.180 |
Why?
|
| Stimulation, Chemical | 1 | 2015 | 14 | 0.180 |
Why?
|
| Ointments | 1 | 2015 | 3 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2016 | 64 | 0.180 |
Why?
|
| Myocardium | 4 | 2008 | 173 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2007 | 108 | 0.170 |
Why?
|
| Africa South of the Sahara | 1 | 2014 | 1 | 0.170 |
Why?
|
| Anilides | 4 | 1987 | 9 | 0.170 |
Why?
|
| Journalism, Medical | 2 | 2008 | 5 | 0.170 |
Why?
|
| Sex Factors | 2 | 2008 | 440 | 0.170 |
Why?
|
| Ventricular Fibrillation | 5 | 2006 | 23 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 393 | 0.170 |
Why?
|
| Europe | 2 | 2005 | 70 | 0.170 |
Why?
|
| Phenothiazines | 4 | 1987 | 4 | 0.170 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 2 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2015 | 84 | 0.160 |
Why?
|
| Structure-Activity Relationship | 2 | 2005 | 54 | 0.160 |
Why?
|
| Safety | 1 | 2014 | 54 | 0.160 |
Why?
|
| Lobbying | 1 | 2013 | 1 | 0.160 |
Why?
|
| Health Insurance Exchanges | 1 | 2013 | 1 | 0.160 |
Why?
|
| Ouabain | 4 | 1983 | 6 | 0.160 |
Why?
|
| Electricity | 1 | 2013 | 10 | 0.150 |
Why?
|
| Organizational Innovation | 2 | 2003 | 19 | 0.150 |
Why?
|
| Isradipine | 1 | 1993 | 3 | 0.150 |
Why?
|
| Pyrrolidines | 4 | 1985 | 15 | 0.150 |
Why?
|
| Bradycardia | 2 | 2005 | 22 | 0.150 |
Why?
|
| Solubility | 2 | 2003 | 38 | 0.150 |
Why?
|
| Investigational New Drug Application | 1 | 1992 | 1 | 0.150 |
Why?
|
| Pain Measurement | 1 | 2015 | 406 | 0.150 |
Why?
|
| Monitoring, Physiologic | 4 | 2008 | 86 | 0.150 |
Why?
|
| International Cooperation | 2 | 2005 | 36 | 0.150 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 43 | 0.150 |
Why?
|
| Competitive Behavior | 1 | 2012 | 6 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 31 | 0.150 |
Why?
|
| Economics, Pharmaceutical | 2 | 2003 | 6 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 26 | 0.150 |
Why?
|
| Thallium Radioisotopes | 1 | 1992 | 4 | 0.150 |
Why?
|
| Dipyridamole | 1 | 1992 | 4 | 0.150 |
Why?
|
| Patient Safety | 1 | 2013 | 43 | 0.150 |
Why?
|
| Double-Blind Method | 5 | 2002 | 502 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2011 | 6 | 0.140 |
Why?
|
| Vitamin K | 1 | 2011 | 6 | 0.140 |
Why?
|
| Factor Xa Inhibitors | 1 | 2011 | 5 | 0.140 |
Why?
|
| Prosthesis Design | 1 | 2014 | 420 | 0.140 |
Why?
|
| Safety-Based Medical Device Withdrawals | 1 | 2011 | 1 | 0.130 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 716 | 0.130 |
Why?
|
| Comorbidity | 2 | 2011 | 474 | 0.130 |
Why?
|
| Molecular Biology | 1 | 2011 | 14 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2011 | 48 | 0.130 |
Why?
|
| Paternalism | 1 | 2010 | 1 | 0.130 |
Why?
|
| Public Policy | 2 | 2001 | 5 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2011 | 14 | 0.130 |
Why?
|
| Florida | 1 | 2010 | 17 | 0.130 |
Why?
|
| Bethanidine | 3 | 1985 | 3 | 0.130 |
Why?
|
| Coronary Artery Disease | 2 | 2004 | 128 | 0.130 |
Why?
|
| Acute Disease | 2 | 2009 | 256 | 0.130 |
Why?
|
| Medicaid | 1 | 2011 | 36 | 0.130 |
Why?
|
| Ticlopidine | 1 | 2010 | 15 | 0.130 |
Why?
|
| Medicare | 1 | 2011 | 72 | 0.130 |
Why?
|
| Industry | 1 | 2010 | 9 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2012 | 119 | 0.120 |
Why?
|
| Exercise Test | 5 | 1995 | 100 | 0.120 |
Why?
|
| Publications | 1 | 2010 | 8 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2011 | 70 | 0.120 |
Why?
|
| Radioisotopes | 1 | 2009 | 15 | 0.120 |
Why?
|
| Lithium Carbonate | 2 | 2000 | 4 | 0.120 |
Why?
|
| Canada | 1 | 2009 | 45 | 0.120 |
Why?
|
| Antimanic Agents | 2 | 2000 | 12 | 0.120 |
Why?
|
| Linear Models | 1 | 2010 | 257 | 0.120 |
Why?
|
| Hepatorenal Syndrome | 1 | 2009 | 1 | 0.120 |
Why?
|
| Glaucoma | 1 | 2009 | 5 | 0.120 |
Why?
|
| Ultrafiltration | 1 | 2009 | 6 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 2009 | 27 | 0.120 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 8 | 0.120 |
Why?
|
| Hepatic Encephalopathy | 1 | 2009 | 6 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2009 | 13 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 22 | 0.110 |
Why?
|
| Liver Failure | 1 | 2009 | 13 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2010 | 216 | 0.110 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 28 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 18 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2008 | 52 | 0.110 |
Why?
|
| Bipolar Disorder | 2 | 2000 | 112 | 0.110 |
Why?
|
| Cotinine | 1 | 2008 | 5 | 0.110 |
Why?
|
| Azetidines | 1 | 2008 | 4 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 60 | 0.110 |
Why?
|
| Research Subjects | 1 | 2008 | 9 | 0.110 |
Why?
|
| Commerce | 1 | 2008 | 9 | 0.110 |
Why?
|
| Prognosis | 2 | 2009 | 845 | 0.110 |
Why?
|
| Simvastatin | 1 | 2008 | 15 | 0.110 |
Why?
|
| Quality Control | 1 | 2008 | 46 | 0.110 |
Why?
|
| Citrus paradisi | 1 | 2007 | 1 | 0.110 |
Why?
|
| Xenopus | 1 | 2007 | 6 | 0.110 |
Why?
|
| Mental Processes | 1 | 2008 | 17 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 20 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 97 | 0.110 |
Why?
|
| Legislation, Medical | 1 | 2007 | 1 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2009 | 90 | 0.100 |
Why?
|
| Motivation | 1 | 2008 | 90 | 0.100 |
Why?
|
| Child | 2 | 2003 | 1335 | 0.100 |
Why?
|
| Natriuresis | 1 | 2007 | 3 | 0.100 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 13 | 0.100 |
Why?
|
| Quinolines | 1 | 2007 | 15 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 31 | 0.100 |
Why?
|
| Access to Information | 1 | 2006 | 5 | 0.100 |
Why?
|
| Confidentiality | 1 | 2006 | 9 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2004 | 1520 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 102 | 0.100 |
Why?
|
| Smoking | 1 | 2008 | 167 | 0.100 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 43 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 552 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 41 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2008 | 264 | 0.100 |
Why?
|
| Probability | 1 | 2006 | 94 | 0.100 |
Why?
|
| Ethanol | 1 | 2008 | 120 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 90 | 0.090 |
Why?
|
| Enterococcus faecalis | 1 | 2006 | 8 | 0.090 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 15 | 0.090 |
Why?
|
| Benzofurans | 1 | 1986 | 4 | 0.090 |
Why?
|
| Acecainide | 1 | 1985 | 1 | 0.090 |
Why?
|
| Tocainide | 4 | 1986 | 4 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 110 | 0.090 |
Why?
|
| Antidepressive Agents | 2 | 2004 | 93 | 0.090 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 3 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 152 | 0.090 |
Why?
|
| Aspirin | 1 | 2006 | 65 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2006 | 208 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 92 | 0.090 |
Why?
|
| Incidence | 1 | 2008 | 692 | 0.090 |
Why?
|
| Lethal Dose 50 | 1 | 2005 | 2 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2005 | 30 | 0.090 |
Why?
|
| Bepridil | 4 | 1985 | 4 | 0.090 |
Why?
|
| Stroke Volume | 3 | 1999 | 51 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 9 | 0.090 |
Why?
|
| Lactones | 1 | 2004 | 14 | 0.090 |
Why?
|
| Sulfones | 1 | 2004 | 25 | 0.090 |
Why?
|
| Guanidines | 1 | 1984 | 2 | 0.090 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2004 | 1 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 291 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2002 | 1775 | 0.080 |
Why?
|
| Colon | 1 | 2006 | 132 | 0.080 |
Why?
|
| Pharmaceutical Solutions | 1 | 2004 | 3 | 0.080 |
Why?
|
| Aconitine | 1 | 2004 | 1 | 0.080 |
Why?
|
| Self Medication | 1 | 2004 | 3 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2006 | 90 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2006 | 760 | 0.080 |
Why?
|
| Purkinje Fibers | 1 | 1983 | 2 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2003 | 36 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2004 | 30 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 67 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 76 | 0.080 |
Why?
|
| SARS Virus | 1 | 2003 | 4 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2003 | 9 | 0.080 |
Why?
|
| World Health Organization | 1 | 2003 | 18 | 0.080 |
Why?
|
| Algorithms | 1 | 2006 | 380 | 0.080 |
Why?
|
| Travel | 1 | 2003 | 14 | 0.080 |
Why?
|
| Spinal Cord | 3 | 1980 | 100 | 0.080 |
Why?
|
| Australia | 1 | 2003 | 38 | 0.080 |
Why?
|
| Encainide | 4 | 1987 | 7 | 0.080 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2002 | 21 | 0.080 |
Why?
|
| Moricizine | 4 | 1987 | 6 | 0.070 |
Why?
|
| Baltimore | 1 | 2002 | 15 | 0.070 |
Why?
|
| Ethics Committees, Research | 1 | 2002 | 4 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2002 | 54 | 0.070 |
Why?
|
| Biological Warfare | 1 | 2002 | 3 | 0.070 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 20 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2002 | 158 | 0.070 |
Why?
|
| Chronic Disease | 2 | 1999 | 465 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 43 | 0.070 |
Why?
|
| Civil Defense | 1 | 2002 | 8 | 0.070 |
Why?
|
| Cardiac Complexes, Premature | 3 | 1986 | 3 | 0.070 |
Why?
|
| Digitalis Glycosides | 2 | 2001 | 3 | 0.070 |
Why?
|
| Ethics Committees | 1 | 2001 | 2 | 0.070 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 9 | 0.070 |
Why?
|
| Age Factors | 1 | 2004 | 794 | 0.070 |
Why?
|
| Awareness | 1 | 2001 | 41 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 122 | 0.070 |
Why?
|
| Disopyramide | 3 | 1986 | 3 | 0.070 |
Why?
|
| Hypocalcemia | 1 | 2001 | 4 | 0.070 |
Why?
|
| Informed Consent | 1 | 2001 | 25 | 0.070 |
Why?
|
| Intestinal Absorption | 1 | 2001 | 44 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2010 | 1042 | 0.070 |
Why?
|
| Tilt-Table Test | 1 | 2000 | 1 | 0.070 |
Why?
|
| Histamine Antagonists | 1 | 1980 | 2 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2001 | 133 | 0.060 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2000 | 6 | 0.060 |
Why?
|
| Propranolol | 2 | 1979 | 13 | 0.060 |
Why?
|
| Aging | 1 | 2010 | 1265 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2001 | 361 | 0.060 |
Why?
|
| Prevalence | 1 | 2002 | 477 | 0.060 |
Why?
|
| Abstracting and Indexing as Topic | 1 | 1999 | 3 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 1999 | 5 | 0.060 |
Why?
|
| Recurrence | 3 | 1991 | 332 | 0.060 |
Why?
|
| Morbidity | 1 | 1999 | 57 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 1999 | 121 | 0.060 |
Why?
|
| Forecasting | 1 | 1999 | 117 | 0.060 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1998 | 6 | 0.060 |
Why?
|
| Needs Assessment | 1 | 1998 | 49 | 0.050 |
Why?
|
| Resuscitation | 1 | 1997 | 13 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1997 | 18 | 0.050 |
Why?
|
| Atrial Flutter | 2 | 1986 | 13 | 0.050 |
Why?
|
| Isosorbide Dinitrate | 1 | 1996 | 1 | 0.050 |
Why?
|
| Echocardiography | 1 | 1997 | 173 | 0.050 |
Why?
|
| Phenytoin | 2 | 1986 | 11 | 0.050 |
Why?
|
| Administration, Sublingual | 1 | 1995 | 1 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1996 | 50 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 1995 | 94 | 0.040 |
Why?
|
| Mutation | 1 | 1997 | 412 | 0.040 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 14 | 0.040 |
Why?
|
| Ajmaline | 2 | 1985 | 2 | 0.040 |
Why?
|
| Aprindine | 2 | 1985 | 2 | 0.040 |
Why?
|
| Bretylium Tosylate | 2 | 1985 | 2 | 0.040 |
Why?
|
| Mexiletine | 2 | 1985 | 2 | 0.040 |
Why?
|
| Propiophenones | 2 | 1985 | 3 | 0.040 |
Why?
|
| Propafenone | 2 | 1985 | 3 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 1999 | 1115 | 0.040 |
Why?
|
| Cost Sharing | 1 | 1992 | 2 | 0.040 |
Why?
|
| Suspensions | 1 | 1992 | 4 | 0.040 |
Why?
|
| Tablets | 1 | 1992 | 6 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 1992 | 62 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 1991 | 8 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 1991 | 46 | 0.040 |
Why?
|
| Liver | 1 | 1993 | 199 | 0.030 |
Why?
|
| Refractory Period, Electrophysiological | 2 | 1987 | 6 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1993 | 212 | 0.030 |
Why?
|
| Kinetics | 3 | 1985 | 279 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1987 | 34 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1987 | 63 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 1986 | 3 | 0.020 |
Why?
|
| Propanolamines | 1 | 1986 | 11 | 0.020 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1986 | 2 | 0.020 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 1986 | 3 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1986 | 37 | 0.020 |
Why?
|
| Heart Atria | 2 | 1985 | 76 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1985 | 16 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 1985 | 14 | 0.020 |
Why?
|
| Protriptyline | 1 | 1984 | 1 | 0.020 |
Why?
|
| Syncope | 1 | 1984 | 7 | 0.020 |
Why?
|
| Rubidium | 1 | 1983 | 6 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1983 | 20 | 0.020 |
Why?
|
| Cats | 3 | 1979 | 80 | 0.020 |
Why?
|
| Promethazine | 1 | 1980 | 1 | 0.020 |
Why?
|
| Cimetidine | 1 | 1980 | 2 | 0.020 |
Why?
|
| Histamine | 1 | 1980 | 10 | 0.020 |
Why?
|
| Histamine H1 Antagonists | 1 | 1980 | 9 | 0.020 |
Why?
|
| Sorbitol | 1 | 1978 | 5 | 0.010 |
Why?
|
| Isosorbide | 1 | 1978 | 2 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1997 | 18 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 71 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1997 | 82 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 85 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1976 | 25 | 0.010 |
Why?
|
| Random Allocation | 2 | 1986 | 141 | 0.010 |
Why?
|
| Digitoxin | 1 | 1974 | 1 | 0.010 |
Why?
|
| Catecholamines | 1 | 1993 | 16 | 0.010 |
Why?
|
| Mathematics | 1 | 1985 | 34 | 0.010 |
Why?
|
| Models, Biological | 1 | 1985 | 418 | 0.000 |
Why?
|
| Mouth Floor | 1 | 1978 | 2 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1976 | 69 | 0.000 |
Why?
|
| Tritium | 1 | 1974 | 17 | 0.000 |
Why?
|